Genelux (GNLX) Non-Current Assets (2022 - 2026)

Genelux (GNLX) posted quarterly Non-Current Assets of $5.6 million for Q1 2026, up 44.16% quarter-over-quarter from $3.9 million in Q4 2025.

Genelux (GNLX) Non-Current Assets (2022 - 2026) Analysis & Trends

Genelux's Non-Current Assets history runs 5 years deep, the most recent figure standing at $5.6 million for Q1 2026.

In Q1 2026, Non-Current Assets changed N/A year-over-year to $5.6 million; the TTM figure through Sep 2025 stood at $3.4 million (down 20.17% YoY), while the FY2025 annual figure was $3.9 million, up 23.01% from the prior year.
Non-Current Assets for Q1 2026 stood at $5.6 million, up from $3.9 million in the prior quarter.
The five-year high for Non-Current Assets was $10.3 million in Q2 2024, with the low at $2.9 million in Q3 2023.
The 5-year median for Non-Current Assets is $3.6 million (2022), against an average of $4.3 million.
The sharpest annual moves came in 2024 and 2025: Non-Current Assets jumped 48.74% in 2024, then sank 70.78% in 2025.
Genelux's Non-Current Assets stood at $3.6 million in 2022, then gained by 1.4% to $3.7 million in 2023, then retreated by 14.15% to $3.2 million in 2024, then grew by 23.01% to $3.9 million in 2025, then jumped by 44.16% to $5.6 million in 2026.
Business Quant data shows GNLX's Non-Current Assets at $5.6 million in Q1 2026, $3.9 million in Q4 2025, and $3.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.96 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	938.60 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	468.65 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	18.06 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	6.80 Bn
10	Genelux	120.53 Mn	120.53 Mn	-	5.62 Mn

Download Data